Regeneron Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Regeneron Pharmaceuticals CEO'su Leonard Schleifer, Jan1988 tarihinde atandı, in görev süresi 36.83 yıldır. in toplam yıllık tazminatı $ 8.18M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.9% maaş ve 77.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.23% ine doğrudan sahiptir ve bu hisseler $ 1.77B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.2 yıl ve 17.9 yıldır.
Anahtar bilgiler
Leonard Schleifer
İcra Kurulu Başkanı
US$8.2m
Toplam tazminat
CEO maaş yüzdesi | 22.9% |
CEO görev süresi | 36.8yrs |
CEO sahipliği | 2.2% |
Yönetim ortalama görev süresi | 7.2yrs |
Yönetim Kurulu ortalama görev süresi | 17.9yrs |
Son yönetim güncellemeleri
Recent updates
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings
Nov 22Regeneron: The Biotech Stock To Buy Now
Nov 19Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sep 25Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$5b |
Jun 30 2024 | n/a | n/a | US$4b |
Mar 31 2024 | n/a | n/a | US$4b |
Dec 31 2023 | US$8m | US$2m | US$4b |
Sep 30 2023 | n/a | n/a | US$4b |
Jun 30 2023 | n/a | n/a | US$4b |
Mar 31 2023 | n/a | n/a | US$4b |
Dec 31 2022 | US$7m | US$2m | US$4b |
Sep 30 2022 | n/a | n/a | US$5b |
Jun 30 2022 | n/a | n/a | US$6b |
Mar 31 2022 | n/a | n/a | US$8b |
Dec 31 2021 | US$6m | US$2m | US$8b |
Sep 30 2021 | n/a | n/a | US$7b |
Jun 30 2021 | n/a | n/a | US$6b |
Mar 31 2021 | n/a | n/a | US$4b |
Dec 31 2020 | US$135m | US$1m | US$4b |
Sep 30 2020 | n/a | n/a | US$3b |
Jun 30 2020 | n/a | n/a | US$3b |
Mar 31 2020 | n/a | n/a | US$2b |
Dec 31 2019 | US$21m | US$1m | US$2b |
Sep 30 2019 | n/a | n/a | US$2b |
Jun 30 2019 | n/a | n/a | US$2b |
Mar 31 2019 | n/a | n/a | US$2b |
Dec 31 2018 | US$27m | US$1m | US$2b |
Sep 30 2018 | n/a | n/a | US$2b |
Jun 30 2018 | n/a | n/a | US$2b |
Mar 31 2018 | n/a | n/a | US$1b |
Dec 31 2017 | US$27m | US$1m | US$1b |
Tazminat ve Piyasa: Leonard 'nin toplam tazminatı ($USD 8.18M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.66M ).
Tazminat ve Kazançlar: Leonard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Leonard Schleifer (71 yo)
36.8yrs
Görev süresi
US$8,184,338
Tazminat
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 36.8yrs | US$8.18m | 2.23% $ 1.8b | |
Co-Founder | 23.8yrs | US$7.76m | 1.07% $ 851.4m | |
Executive Vice President of Research | 5.8yrs | US$8.43m | 0.048% $ 38.0m | |
Executive VP and GM of Industrial Operations & Product Supply | 16.6yrs | US$8.76m | 0.031% $ 25.0m | |
Senior VP of Finance & CFO | less than a year | Veri yok | 0.017% $ 13.8m | |
Senior Vice President of Quality Assurance & Operations | 4.8yrs | Veri yok | Veri yok | |
Senior VP of IT & Chief Information Officer | 3.8yrs | Veri yok | Veri yok | |
Senior Vice President of Investor Relations & Strategic Analysis | no data | Veri yok | Veri yok | |
Executive VP | 13.2yrs | US$7.13m | 0.036% $ 28.3m | |
Senior VP & Chief Compliance Officer | 1.8yrs | Veri yok | Veri yok | |
Senior Vice President of Corporate Affairs | no data | Veri yok | Veri yok | |
Executive Vice President of Human Resources | 8.6yrs | Veri yok | Veri yok |
7.2yrs
Ortalama Görev Süresi
64.5yo
Ortalama Yaş
Deneyimli Yönetim: REGN 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.2 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 36.8yrs | US$8.18m | 2.23% $ 1.8b | |
Co-Founder | 23.8yrs | US$7.76m | 1.07% $ 851.4m | |
Lead Independent Director | 14yrs | US$748.01k | 0.00073% $ 579.6k | |
Independent Director | 21.8yrs | US$724.99k | 0.016% $ 13.0m | |
Independent Director | 33.4yrs | US$728.99k | 0.012% $ 9.3m | |
Independent Director | 33.4yrs | US$709.99k | 0.0046% $ 3.7m | |
Independent Director | 36.8yrs | US$724.99k | 0.026% $ 21.0m | |
Independent Director | 7.8yrs | US$704.99k | 0.000010% $ 7.9k | |
Independent Director | 2.1yrs | US$247.79k | 0% $ 0 | |
Independent Director | 8.2yrs | US$714.99k | 0% $ 0 | |
Independent Director | 8.2yrs | US$709.99k | 0.0013% $ 1.0m | |
Independent Director | 1.2yrs | US$1.03m | 0% $ 0 |
17.9yrs
Ortalama Görev Süresi
71yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: REGN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 17.9 yıldır).